Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 function

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Muret, Jane ^a   Hasmim, Meriem ^a   Stasik, Izabela ^a   Jalil, Abdelali ^a   Mallavialle, Aude ^b   Nanbakhsh, Arash ^a   Lacroix, Ludovic ^a   Billot, Katy ^c,d,e   Baud, Véronique ^c,d,e   Thiery, Jérome ^a   Vielh, Philippe ^a   Terrier, Philippe ^a   Wiels, Joelle ^f   Vassilev, Lyubomir ^g   Lecesne, Axel ^a   Bonvalot, Sylvie ^a   Chouaib, Salem ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c INSTITUT COCHIN   (France)

^d CNRS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UMR 8126   (France)

^g HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA BINDING; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENDOTHELIUM CELL; EX VIVO STUDY; GENE; GENE CONTROL; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; SARCOMA CELL; SOFT TISSUE SARCOMA; TP53 GENE;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; GENES, P53; HUMANS; IN SITU NICK-END LABELING; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; SARCOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862489220     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038808     Document Type: Article

References (46)

1. Grimer R, Athanasou N, Gerrand C, Judson I, Lewis I, et al. (2010) UK Guidelines for the Management of Bone Sarcomas. Sarcoma 2010: 317462.
2. Casali PG, Blay J-Y, (2010) Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21: 198-203.
3. Lejeune FJ, Liénard D, Matter M, Rüegg C, (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6: 6.
4. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, et al. (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224: 756-764.
5. Bonvalot S, Laplanche A, Lejeune F, Stoeckle E, Le Péchoux C, et al. (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16: 1061-1068.
6. Renard N, Nooijen PT, Schalkwijk L, De Waal RM, Eggermont AM, et al. (1995) VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol 176: 279-287.
7. Eggermont AM, (1998) TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res 18: 3899-3905.
8. Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, et al. (1996) Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 74: 1908-1915.
9. Rüegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, et al. (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4: 408-414.
10. Menon C, Ghartey A, Canter R, Feldman M, Fraker DL, (2006) Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann. Surg 244: 781-791.
11. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, et al. (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82: 1000-1003.
12. Plaat BE, Molenaar WM, Mastik MF, Koudstaal J, van den Berg E, et al. (1999) Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin Cancer Res 5: 1650-1657.
13. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, et al. (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945.
14. Balkwill F, (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371.
15. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E, et al. (1988) Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 6: 344-350.
16. Lejeune F, Liénard D, Eggermont A, Schraffordt Koops H, Rosenkaimer F, et al. (1994) Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem 56: 52-61.
17. Beyaert R, Fiers W, (1994) Molecular mechanisms of tumor necrosis factor-induced cytotoxicity: What we do understand and what we do not. FEBS Letters 340: 9-16.
18. Cai Z, Capoulade C, Moyret-Lalle C, Amor-Gueret M, Feunteun J, et al. (1997) Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 15: 2817-2826.
19. Ameyar M, Shatrov V, Bouquet C, Capoulade C, Cai Z, et al. (1999) Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb. Oncogene 18: 5464-5472.
20. Muret J, Yacoub M, Terrier P, Drusch F, Laplanche A, et al. (2008) p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann Oncol 19: 793-800.
21. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
22. Pérot G, Chibon F, Montero A, Lagarde P, de Thé H, et al. (2010) Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol 177: 2080-2090.
23. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799.
24. Wang W, El-Deiry WS, (2008) Restoration of p53 to limit tumor growth. Curr Opin Oncol 20: 90-96.
25. Foster BA, Coffey HA, Morin MJ, Rastinejad F, (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510.
26. Wang W, Takimoto R, Rastinejad F, El-Deiry WS, (2003) Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23: 2171-2181.
27. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
28. Vassilev LT, (2007) MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31.
29. Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, et al. (2009) Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 101: 1562-1574.
30. Sekiguchi M, Shiroko Y, Suzuki T, Imada M, Miyahara M, et al. (1985) Characterization of a human rhabdomyosarcoma cell strain in tissue culture. Biomed Pharmacother 39: 372-380.
31. Lee G, Chae H, Kim H, (2011) Monoamine carboxylate transporters are involved in BI-1-associated cancer metastasis in HT1080 colon fibrosarcoma cells. Int J Oncol 39: 209-216.
32. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, et al. (2007) Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 121: 199-205.
33. Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, et al. (2011) MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer 11: 1-11.
34. Chibon F, Mariani O, Derré J, Malinge S, Coindre JM, et al. (2002) A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet. Cytogenet 139: 24-29.
35. Pérot G, Derré J, Coindre J-M, Tirode F, Lucchesi C, et al. (2009) Strong Smooth Muscle Differentiation Is Dependent on Myocardin Gene Amplification in Most Human Retroperitoneal Leiomyosarcomas. Cancer Research 69: 2269-2278.
36. Jacque E, Tchenio T, Piton G, Romeo P-H, Baud V, (2005) RelA repression of RelB activity induces selective gene activation downstream of TNF receptors. Proc Natl Acad Sci U.S.A. 102: 14635-14640.
37. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, et al. (2002) The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1: 47-55.
38. Beg AA, Baltimore D, (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784.
39. Drané P, Leblanc V, Miro-Mur F, Saffroy R, Debuire B, et al. (2002) Accumulation of an inactive form of p53 protein in cells treated with TNF alpha. Cell Death Differ 9: 527-537.
40. Menon C, Iyer M, Prabakaran I, Canter RJ, Lehr SC, et al. (2003) TNF-alpha downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model. Am J Physiol Heart Circ Physiol 284: H317-329.
41. Cheok CF, Verma CS, Baselga J, Lane DP, (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
42. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, et al. (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106: 3150-3159.
43. Scian MJ, Stagliano KER, Anderson MAE, Hassan S, Bowman M, et al. (2005) Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25: 10097-10110.
44. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, et al. (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67: 2396-2401.
45. Bezzi M, Hasmim M, Bieler G, Dormond O, Rüegg C, (2003) Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278: 43603-43614.
46. Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP, (2007) Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle 6: 2178-2185.